LLY News
-
LLY neutral
They built exoskeletons for stroke patients. Now, their robots can do eyelash extensions
fortune.com·Sep 9, 2026·Amanda Gerut here, pinch hitting for Allie. I was born into a family of sparse eyelashes. Some people have thick, natural doe eyes; for others it’s Maybelline...
-
LLY neutral
LLY Looks 23.0% Undervalued on GF Value™ Amid Strategic Merida Biosciences Acquisition
gurufocus.com·Aug 31, 2026·On August 31, 2026, Eli Lilly and Co (NYSE: LLY) announced its intent to acquire Merida Biosciences for up to $2.875 billion, a move that underscores Lilly’s ...
-
LLY bullish
LLY Looks 22.7% Undervalued on GF Value™ After Mounjaro's Cardiovascular Approval
gurufocus.com·Aug 28, 2026·On August 28, 2026, Eli Lilly and Co (NYSE: LLY) announced FDA approval for an expanded indication of its GLP-1 drug, Mounjaro (tirzepatide), to reduce the risk...
-
LLY neutral
Fidelity vs VanEck Healthcare ETFs: Broad Exposure or Pharma Focus
finance.yahoo.com·Aug 26, 2026·The VanEck Pharmaceutical ETF offers a more concentrated approach with only 26 holdings, focused exclusively on the healthcare sector. Top holdings include Eli ...
-
LLY bearish
LLY Looks 18.8% Undervalued on GF Value™
gurufocus.com·Aug 26, 2026·On August 26, 2026, Eli Lilly and Co (NYSE: LLY) announced compelling study results showing that prolonged use of its weight loss drug Zepbound significantly re...
-
LLY neutral
LLY Looks 18.8% Undervalued on GF Value™ as Cost-Saving Study Boosts Outlook
gurufocus.com·Aug 26, 2026·On August 26, 2026, Eli Lilly and Co (NYSE: LLY) announced compelling results from a study demonstrating that its weight management drug Zepbound significantly ...
-
LLY neutral
Philip Morris International (PM) vs. Altria Group (MO): Which Tobacco Dividend Fits Your Portfolio
insidermonkey.com·Aug 19, 2026·Philip Morris International Inc. (NYSE:PM) and Altria Group, Inc. (NYSE:MO) often come up in the same conversation when investors look for tobacco dividend stoc...
-
LLY bullish
InduPro raises $77M, begins first human trial of cancer drug
geekwire.com·Aug 14, 2026·Chronicling the Seattle and Pacific Northwest startup scene. SEE MORE InduPro’s ARRIS platform is designed to bring two proteins on the surface of a cell tog...
-
LLY bullish
OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests
manilatimes.net·Aug 13, 2026·Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside MIAMI, Fla., Aug. ...
-
LLY neutral
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter 2026
manilatimes.net·Aug 7, 2026·Tokyo, Japan and Cambridge, UK, 7August 2026 - Nxera Pharma ("the Company” or "Nxera”; TSE: 4565) provides an update on operational activities and reports i...
-
LLY neutral
Eli Lilly: Fine Q2 2026 Results, But Alertness Required (NYSE:LLY)
seekingalpha.com·Aug 6, 2026·Eli Lilly and Company ( LLY ) gained 4.7% yesterday following the pre-market release of its Q2 2026 results , marking the biggest single session gains since I l...
-
LLY bullish
Pfizer Inc. (PFE) vs. Eli Lilly and Company (LLY): The Growth vs. Value Play in Pharma
insidermonkey.com·Jul 30, 2026·Pfizer (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) offer unique divergent investment opportunities in the pharmaceutical industry. While one acts as a value...
-
LLY bullish
Amylin Analogs and Combination Therapies Clinical Trial Landscape Expands as 15+ Leading Companies Accelerate Drug Development | DelveInsight
manilatimes.net·Jul 28, 2026·The amylin analogs and combination therapies competitive landscape report delivers important insights into approved as well as ongoing research of 20+ pipeline ...
-
LLY neutral
Questex’s Fierce Pharma Unveils Fierce Pharma Week’s 2026 Conference Program, Explores What’s Next in the Pharmaceutical Industry
manilatimes.net·Jul 28, 2026·Health Advocate Tamsen Fadal will Deliver Keynote Offering Fresh Perspectives on Leadership, Resilience, Innovation and the Power of Storytelling Fierce Pharma...
-
LLY neutral
Claris Bio Unveils Development Strategy, Planned Pivotal Study Supported by $118 Million Series B Financing from Top-Tier Investors, and Multiple Leadership Appointments
manilatimes.net·Jul 28, 2026·Positive proof-of-concept clinical data show substantial improvements in visual acuity in limbal stem cell deficiency (LSCD) patients treated with CSB-001 Pivo...
-
LLY bearish
PJP vs. IYH: Which Healthcare ETF Is the Better Buy?
finance.yahoo.com·Jul 20, 2026·The iShares U.S. Healthcare ETF (NYSEMKT:IYH) provides broad exposure to the medical sector at a lower cost, while the Invesco Pharmaceuticals ETF (NYSEMKT:PJP)...
-
LLY neutral
IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors?
finance.yahoo.com·Jul 19, 2026·Investors comparing the iShares U.S. Pharmaceuticals ETF (NYSEMKT:IHE) and the iShares Global Healthcare ETF (NYSEMKT:IXJ) must choose between concentrated U.S....
-
LLY neutral
Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 - The Stock Now Trades Above $1,200
manilatimes.net·Jul 17, 2026·NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Atlas Healthcare Fund managed by VST Capital , today highlighted a series of early conviction investment decisions t...
-
LLY neutral
AdvanCell Closes $315 Million Series D
vcnewsdaily.com·Jul 16, 2026·AdvanCell Closes $315 Million Series D Back to Home BOSTON, MA, AdvanCell, a clinical-stage radiopharmaceutical company, announced the closing of an oversubscr...
-
LLY neutral
Tuberculosis Clinical Trial Pipeline Shows Potential with Active Contributions from 28+ Key Companies | DelveInsight
manilatimes.net·Jul 14, 2026·The tuberculosis clinical trial analysis report delivers important insights into ongoing research of 30+ pipeline tuberculosis drugs, clinical strategies, upcom...
-
LLY bullish
Wall Street Lifts Obesity Drug Targets for Eli Lilly and AbbVie as Medicare Coverage Expands
investorideas.com·Jul 10, 2026·Biotech · Markets Commentary NYSE: LLY JPMorgan lifted Eli Lilly to $1,400 and AbbVie drew a string of target hikes as a new Medicare GLP-1 program widens acc...
-
LLY neutral
Flare Therapeutics Secures $85M Series C Round
vcnewsdaily.com·Jul 10, 2026·Flare Therapeutics Secures $85M Series C Round Back to Home CAMBRIDGE, MA, Flare Therapeutics, a clinical-stage biotechnology company, announced the closing of...
-
LLY neutral
Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%
finance.yahoo.com·Jul 9, 2026·Quick Read OZEM holds Lilly at 16% and Novo Nordisk at 13%, concentrating nearly 30% in GLP-1 leaders versus XLV's diluted multi-sector exposure. OZEM rounds ...
-
LLY bearish
Inside THNR: A Leaner Approach to Weight Loss Investing
etftrends.com·Jul 7, 2026·Demand for GLP-1 weight loss drugs has reshaped the healthcare industry. And ETFs such as the Amplify Weight Loss Drug & Treatment ETF (THNR) give investors a w...
-
LLY bearish
CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?
finance.yahoo.com·Jul 7, 2026·Viking Therapeutics is a clinical-stage biopharmaceutical company that develops therapies for metabolic and endocrine disorders. Its primary focus is on obesity...
-
LLY bullish
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
finance.yahoo.com·Jul 6, 2026·Can high-flying growth justify a premium valuation, or is a recovered value play the safer bet for 2026? Investors are weighing Eli Lilly and (NYSE:LLY) against...
-
LLY bullish
Eli Lilly and Company (LLY) Fell on Regulatory And Pricing Policy Challenges
insidermonkey.com·Jul 6, 2026·When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward...
-
LLY neutral
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
zacks.com·Jul 6, 2026·We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All...
-
LLY neutral
Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years?
finance.yahoo.com·Jul 6, 2026·The short, but glib, answer to the headline question posed for Viking Therapeutics (NASDAQ: VKTX) investors is "no," because the likelihood is that the $4.6 bil...
-
LLY bearish
IHE vs. PJP: Which Pharmaceutical ETF Is the Better Buy for Investors?
finance.yahoo.com·Jul 5, 2026·The iShares U.S. Pharmaceuticals ETF (NYSEMKT:IHE) offers lower fees and a higher dividend yield, while the Invesco Pharmaceuticals ETF (NYSEMKT:PJP) spreads it...
-
LLY bullish
Dividend King vs. Growth Giant: Johnson & Johnson Takes on Eli Lilly
finance.yahoo.com·Jul 4, 2026·Quick Read Mounjaro and Zepbound drove Lilly's revenue up 56% while JNJ grew 10% and extended its dividend streak to 64 consecutive years. Lilly partnered wit...
-
LLY neutral
Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
manilatimes.net·Jun 30, 2026·SAN FRANCISCO and SUZHOU, China, June 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that...
-
LLY neutral
Eli Lilly and Company (LLY) Up More Than 6% Over the Past Month, Can it Move Higher?
finance.yahoo.com·Jun 29, 2026·Eli Lilly and Company (NYSE:LLY) is one of the Stocks That Will Make You Rich Over the Next 3 Years. Eli Lilly and Company (NYSE:LLY) has gained roughly 6% over...
-
LLY bullish
Eli Lilly and Company (LLY) Up More Than 6% Over the Past Month, Can it Move Higher?
insidermonkey.com·Jun 29, 2026·When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward...
-
LLY neutral
Harbour BioMed Appoints Dr. Lloyd Klickstein as Scientific Advisor for Immunology
manilatimes.net·Jun 29, 2026·CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , June 29, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical c...
-
LLY neutral
Is Eli Lilly and Company (LLY) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds?
finance.yahoo.com·Jun 28, 2026·Eli Lilly and Company (NYSE:LLY) is among the Best Healthcare Stocks Stocks.On June 23, Reuters reported that Eli Lilly and Company (NYSE:LLY) expects to launch...
-
LLY neutral
Lilly launches cancer therapy drug Tanstrive
thehindubusinessline.com·Jun 25, 2026·Eli Lilly and Company India Pvt Ltd has launched Tanstrive (selpercatinib) in India, for patients with locally advanced or metastatic solid tumors with a rearra...
-
LLY neutral
Tanstrive cost, dosage: Eli Lilly launches cancer drug in India, priced at ₹2.15 lakh per box
livemint.com·Jun 25, 2026·Eli Lilly and Company India on Thursday announced the launch of its cancer treatment drug Tanstrive in India. The launch follows marketing authorisation from t...
-
LLY neutral
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
manilatimes.net·Jun 25, 2026·LEIDEN, Netherlands and CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) ("ProQR”), a clinical-stage biotechnology c...
-
LLY bullish
Eli Lilly and Company (LLY) – Among the 10 Reliable Dividend Stocks to Buy for Long-Term Investors
insidermonkey.com·Jun 25, 2026·When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward...